Corpus ID: 27000520

Technology evaluation: SGN-15, Seattle Genetics Inc.

@article{Smith2001TechnologyES,
  title={Technology evaluation: SGN-15, Seattle Genetics Inc.},
  author={S. Smith},
  journal={Current opinion in molecular therapeutics},
  year={2001},
  volume={3 3},
  pages={
          295-302
        }
}

S. Smith

Published 2001

Biology, Medicine

Current opinion in molecular therapeutics

Seattle Genetics is developing SGN-15 (BMS-182248, BR96-DOX), a monoclonal antibody-doxorubicin conjugate licensed from Bristol-Myers Squibb (BMS) for the potential treatment of cancer, which is currently in phase II trials [283767], [305881], [391927]. BMS had licensed technology from Enzon to help antibodies such as SGN-15 penetrate tumors more efficiently [174538]. BMS also had an R&D agreement with Genzyme for the production of SGN-15 in transgenic goats milk [177921]. In 1993, Ixsys (now… CONTINUE READING

View on PubMed

Save to Library

Create Alert

Cite

Launch Research Feed